Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LAE001 in Metastatic Prostate Cancer
NCT03843918Phase 2Terminated
- Sponsor
- Laekna
- Start
- Apr 2019
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of CFG920 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Laekna. Started Apr 2019; status: terminated.
02
Drugs
CFG920
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03843918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03843918.